Tramford International Announces Bamboo Flavone Patent Approved

HONG KONG, Nov 23, 2005 /Xinhua-PRNewswire-FirstCall via COMTEX/ -- Tramford International Limited (TRFDF) (''Tramford'' or the ''Company'') announced that the patent of ''bamboo flavone application in anti-prostate disease drug" developed by Future Solutions Development Inc. (''FSD''), the newly acquired subsidiary of the Company, was approved by China's State Intellectual Property Bureau in November, 2005. Along with this approval, the same patent also received approval from Patent Cooperation Treaty (PCT), the international patent registration and administration organization. The Treaty makes it possible to seek patent protection for an invention simultaneously in each of a large number of countries by filing an "international" patent application. FSD filed this patent under PCT for China, U.S. and Japan. The approval is the first step for FSD to enter into the markets in U.S. and Japan.

The scientists at FSD discovered that bamboo flavone is effective in relief symptoms of inflammation due to prostatitis, prostatic hyperplasia and prostate cancer.

About 50% of male in the world is affected by prostate illnesses (including prostatitis, prostatic hyperplasia and prostate cancer) in their lifetime. Many patients develop chronicle symptoms. The bamboo flavone, as a natural extract ingredient, poses no long-term side effects to human body. It is a viable option in fighting the illness.

About Tramford International

Tramford International Limited is engaged primarily in providing information network security solutions in People's Republic of China. The Company's certified hardware and software products are used by numerous Chinese business enterprises, financial institutions and government agencies and have been rewarded as the leading network security solutions in China. The Company also provides information management system for port operations. With the recent acquisition of FSD, which develops healthfood products utilizing bio-active components of bamboo, Tramford will enter the Chinese nutraceutical market. Tramford's major shareholder is Beijing Holdings Limited, a conglomerate with over $3 billion in total assets owned by the Beijing People's Municipal Government. For more information, please visit our website at .

Forward-Looking Statement Disclosure

This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The statements regarding Tramford contained in this press release that are not historical in nature, particularly those that utilize terminology such as "may," "will," "should," "likely," "expects," "anticipates," "estimates," "believes" or "plans," or comparable terminology, are forward-looking statements. Forward- looking statements are based on current expectations and assumptions, and entail various risks and uncertainties that could cause actual results to differ materially from those expressed in such forward-looking statements. Important factors known to Tramford that cause actual results to differ materially from those expressed in such forward-looking statements are identified and discussed in Tramford's filings with the Securities and Exchange Commission.

Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.